Breaking barriers in antibody-mediated neurological diseases: From mechanisms to treatment
Workshop internazionale RES di 9 crediti ECM su malattie neurologiche anticorpo-mediate (miastenia gravis, encefalite autoimmune, NMOSD, MOGAD): diagnosi avanzata, nuovi biomarcatori, terapie biologiche e immunoterapia per neurologi, farmacisti, infermieri. Roma, 20-21 novembre 2026.
Fonte dati per questo evento: Agenas. Evento organizzato da provider terzo. Smart ECM riporta dati pubblici dell'evento a scopo informativo e non è responsabile né del corso né dei contenuti, né ha accordi commerciali o di collaborazione con il provider.
Razionale scientifico
Myasthenia gravis (MG) is a prototypical neurological autoimmune disorder affecting the neuromuscular junction. Its hallmark clinical feature is fluctuating muscle weakness caused by pathogenic antibodies targeting the nicotinic Acetylcholine Receptor or the Muscle-specific kinase expressed on the post-synaptic membrane. MG has long served as a model for autoimmune neurological diseases, offering critical insights into the antibody-mediated pathogenic mechanisms and guiding advances in immunotherapy. In recent years, parallel advances have occurred in Autoimmune Encephalitis (AE), Neuromyelitis Optica Spectrum Disorders (NMOSD), and MOG Antibody-Associated Disease (MOGAD). These conditions, like MG, exemplify how pathogenic autoantibodies against neuronal or glial targets drive highly specific clinical syndromes. The development of novel diagnostic tools and innovative treatment approaches have brought opportunities and challenges. This International Workshop will provide a multidisciplinary platform to give an update on the diagnosis and treatment antibody-mediated neurological diseases, highlighting both shared mechanisms and disease-specific features. The landscape for the diagnosis and treatment of antibody-mediated neurological diseases is characterized by both progress and challenges. Notably, new assays for antibody testing have become available, necessitating the comparison of their relative specificity and sensitivity, and the standardization of these tests to improve diagnostic accuracy. Furthermore, several new therapeutic agents are now available, enhancing patient outcomes but also posing a challenge in selecting the most appropriate treatment. As the treatment landscape rapidly evolves, it underscores the critical importance of continuous education to ensure healthcare professionals stay informed about the latest and most effective methods.
Luogo
Nazionale Spazio Eventi
Via Palermo, 10, Roma (RM)
Programma
Day 1 – Navigating the treatment landscape of Myasthenia Gravis· Nazionale Spazio Eventi, Via Palermo 10, Rome
- 14:00Opening RemarksRaffaele Iorio (Italy)
- 14:10The debate: Corticosteroids in Myasthenia Gravis: Still the Backbone of Therapy or Fading Role?Nils Erik Gilhus (Norway), Heinz Wiendl (Germany)
- 15:00Thymectomy in Myasthenia Gravis: Indications and Emerging Evidence from Clinical and Pathological StudiesSpeaker to be announced
- 15:25The Role of Conventional Immunosuppressants in MG Management in the era of innovative therapiesSpeaker to be announced
- 15:50Coffee Break
- 16:10Upstream or Downstream? An Overview of Emerging Biologics Targeting the MG Pathological CascadePushpa Narayanaswami (USA)
- 16:35B-Cell Depletion in Myasthenia Gravis: Current Role and Future PerspectivesMiriam L. Fichtner (Germany)
- 17:00Complement Inhibitors: Emerging Concepts to Guide Personalized TherapyTobias Ruck (Germany)
- 17:25FcRn Antagonists: Practical Clues for Optimizing Cyclic and ContinuousCarlo Antozzi (Italy)
- 17:50Q&A
- 18:10End of Day 1
Day 2 – From mechanisms to treatment· Nazionale Spazio Eventi, Via Palermo 10, Rome
- 09:15The role of Central tolerance in autoimmune neurological diseasesBergithe Oftedal (Norway)
- 09:40Helping the B cells: the role of T cells in neurological autoimmunityCarina Saggau (Germany)
- 10:05B cells in antibody-mediated neurological disordersSarosh Irani (USA)
- 10:30IgG4-mediated autoimmune neurological disordersInga Koneczny (Austria)
- 10:55Coffee break
- 11:15The debate: Without recombinant human monoclonal antibodies, we cannot definitely prove pathogenicity in antibody-mediated neurological disordersJacob Kreye (Germany), Michael Wilson (USA)
- 12:05Neuropathology of Autoimmune EncephalitisSpeaker to be announced
- 12:30Autoimmune Encephalitis: Key Steps for Timely Diagnosis and ManagementJerome Honnorat (France)
- 12:55Traditional and advanced Neuroimaging of Autoimmune encephalitisCarsten Finke (Germany)
- 13:15Lunch and Poster Session
- 14:00Neuropathology of MOGAD and AQP4 autoimmunityGabriele De Luca (UK)
- 14:25Traditional and advanced Neuroimaging of AQP4 and MOG autoimmunityEoin Flanagan (USA)
- 14:50Treatment strategies for NMOSDPaul Friedmann (Germany)
- 15:15Closing RemarksRaffaele Iorio (Italy)
- 15:20End of The Workshop
Responsabili del corso
FOR.MED.SRL
Provider
ID Provider: N° 4695
Città: Genova (GE)
Tipologia: Società, Agenzie Ed Enti Privati
Stato accreditamento: Standard - 1° Rinnovo
Prof. Raffaele Iorio
Responsabile scientifico
Specializzazione: Neurologia
Struttura: Università Cattolica del Sacro Cuore, Roma, Dipartimento di Neuroscienze
Ruolo: Professore Associato di Neurologia
Con il contributo non vincolante di
- TBD
Domande frequenti
L'evento è accreditato per: Farmacista (Farmacista Pubblico Del Ssn); Medico Chirurgo (Neurologia, Chirurgia Toracica); Farmacista (Farmacista Di Altro Settore); Medico Chirurgo (Anestesia E Rianimazione, Medicina Generale (Medici Di Famiglia)); Farmacista (Farmacista Territoriale); Infermiere (Infermiere).
Fonte dati per questo evento: Agenas. Evento organizzato da provider terzo. Smart ECM riporta dati pubblici dell'evento a scopo informativo e non è responsabile né del corso né dei contenuti, né ha accordi commerciali o di collaborazione con il provider.